OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the
Group")
ProBiotix Health plc - response to
requisition notice
OptiBiotix Health plc ("OptiBiotix") notes the
announcement made by ProBiotix Health plc (AQSE: PBX), the life
sciences business developing probiotics to support cardiometabolic
health, on 25 September 2024, that it has received a notice
requisitioning a General Meeting (the "Requisition Notice") which has been
served by Platform Securities Nominees Limited, on behalf of Seneca
Partners.
OptiBiotix is aware of the Requisition Notice
and of the detailed reasons given by Seneca Partners for resorting
to this course of action.
OptiBiotix intends to vote its holding of
53,533,333 ordinary shares in support of the resolutions proposed
by Seneca Partners and will publish its full reasons for supporting
the proposals put forward by Seneca Partners in due
course.
In the meantime, OptiBiotix believes that it is
important that ProBiotix Health plc clarify its issued share
capital which is stated to be 158,166,666 shares carrying voting
rights in its announcement of 4 September 2024 but is stated to be
121,666,666 shares carrying voting rights on its website at
https://probiotixhealth-ir.com/share-information/shareholder-information.
Neil Davidson,
Chairman of OptiBiotix Health plc said: "I am sure that Seneca Partners have
only taken this action as an institutional shareholder after much
careful consideration and for good reason. Shareholder activism led
by institutional shareholders is an important aspect of corporate
governance and should generally be seen as an indication that
serious failings have been identified which need to be addressed in
the best interests of all shareholders."
|
For further
information, please contact: OptiBiotix Health
plc
|
www.optibiotix.com
|
|
Neil Davidson, Chairman
|
Contact via Walbrook
below
|
|
Stephen O'Hara, Chief Executive
|
|
|
|
|
|
Cairn
Financial Advisers LLP (NOMAD)
|
Tel: 020 7213
0880
|
|
Liam Murray / Jo Turner / Ludovico
Lazzaretti
|
|
|
|
|
|
Peterhouse
Capital Limited (Broker)
|
Tel: 020 7220
9797
|
|
Duncan Vasey / Lucy Williams
|
|
|
|
|
|
Walbrook PR
Ltd
|
Mob: 07876 741
001
|
|
Anna Dunphy
|
|
|
|
| |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI),
which was formed in March 2012, brings science to the development
of compounds which modify the human microbiome - the collective
genome of the microbes in the body - in order to prevent and manage
human disease and promote wellness.
OptiBiotix has an extensive R&D
programme working with leading academics in the development of
microbial strains, compounds, and formulations which are used as
active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements
with OptiBiotix to incorporate their human microbiome modulators
into a wide range of food products and drinks.
OptiBiotix is also developing its
own range of consumer supplements and health products. The
Company's current areas of focus include obesity, cardiovascular
health, and diabetes.
